Skip to main content

Elicio Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 29, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 29, 2024

ELTX$1.65+8.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 16. Form 10-K Summary

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: March 29, 2024

By: /s/ Robert Connelly

Robert Connelly

Chief Executive Officer

Power of Attorney

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Robert Connelly and Brian Piekos, and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed by the following persons in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Robert ConnellyRobert ConnellyChief Executive Officer, President and DirectorMarch 29, 2024
(Principal Executive Officer)
/s/ Brian PiekosChief Financial OfficerMarch 29, 2024
Brian Piekos(Principal Financial Officer and Principal Accounting Officer)
/s/ Jay Venkatesan, M.D.DirectorMarch 29, 2024
Jay Venkatesan, M.D.
/s/ Julian Adams, Ph.D.DirectorMarch 29, 2024
Julian Adams, Ph.D.
/s/ Carol AsheDirectorMarch 29, 2024
Carol Ashe
/s/ Yekaterina (Katie) ChudnovskyDirectorMarch 29, 2024
Yekaterina (Katie) Chudnovsky
/s/ Robert R. Ruffolo, Jr., Ph.D.DirectorMarch 29, 2024
Robert R. Ruffolo, Jr., Ph.D.
/s/ Karen WilsonDirectorMarch 29, 2024
Karen Wilson
/s/ Allen Nissenson, M.D.DirectorMarch 29, 2024
Allen Nissenson, M.D.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.